October 2020 Report

New and First Time
Generic Drug Report

New Brand Drug Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update
Tramadol Oral Solution (Qdolo™) Opioid Agonist Pain Launch pending. Approved September 1, 2020.
Oliceridine (Olinvyk™) Injection Opioid Agonist Pain Launch anticipated following DEA assigning controlled substance schedule. Approved August 7, 2020.
Metoclopramide Nasal Spray (Gimoti™) Gastrointestinal Agent Gastroparesis Launch anticipated Q4 2020. Approved June 19, 2020.
Celecoxib Oral Liquid (Elyxyb™) NSAID Migraine Headache Treatment Launch pending. Approved May 5, 2020.
Benzhydrocodone HCl/
Acetaminophen
(Apadaz™)
Opioid Analgesic –
Immediate Release
Pain Launch pending. Approved February 23, 2018.
Buprenorphine Depot
Injection
(Brixadi™)
Opioid Agonist Treatment of
Opioid Addiction
Anticipated approval December 1, 2020 following
expiration of exclusivity period for Sublocade™.
Zolmitriptan (Qtrypta™) Patch Migraine Agent Migraine Headache Treatment FDA review pending.
Celecoxib/Tramadol NSAID/Opioid Agonist Pain FDA review pending.
Ansofaxine Antidepressant Major Depressive Disorder FDA review anticipated December 2020.
Naloxone Injection (Zimhi™) Opioid Antagonist Opioid Overdose FDA declined to approve November 2019.

Generic Pipeline

Medication (Brand name) Drug Class Therapeutic Use Status Update
Apixaban (Eliquis®) Anticoagulant Treatment/Prophylaxis of Deep Vein Thrombosis Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Naloxone HCl
(Narcan®) Nasal Spray
Opioid Antidote Opioid Overdose Launch pending. Generic approved April 19, 2019.

Available in the Last 12 Months

Medication (Brand name) Drug Class Therapeutic Use Status Update
Rimegepant (Nurtec™ ODT) CGRP Antagonist Migraine Headache Treatment March 2020
Ubrogepant (Ubrelvy™) CGRP Antagonist Migraine Headache Treatment March 2020
Lasmiditan (Reyvow™) Migraine Agent Migraine Headache Treatment January 2020

Newly Available Generics

Medication (Brand name) Drug Class Therapeutic Use Status Update
Emtricitabine/Tenofovir (Truvada®) Antiretroviral HIV Post-Exposure Prophylaxis October 2020
Albuterol Sulfate (Proventil® HFA) Inhaled Bronchodilator Asthma April 2020
Naproxen/Esomeprazole (Vimovo®) NSAID/GI Protectant Pain/Stomach Ulcer Prophylaxis February 2020
Albuterol Sulfate (ProAir® HFA) Inhaled Bronchodilator Asthma February 2020
Hydrocodone Bitartrate (Zohydro® ER) Opioid Analgesic – Extended Release Pain January 2020
Doxepin (Silenor®) Tricyclic Antidepressant Sleep Disorders January 2020

Discontinuations & Withdrawals

Medication (Brand name) Drug Class Therapeutic Use Status Update
Albuterol Sulfate Inhaled Bronchodilator Asthma Perrigo Company recalled all lots of its generic September 2020 due to reports of clogged inhalers preventing accurate dosing.
Ranitidine (Zantac®) H-2 Receptor Antagonist Heartburn/Stomach Ulcer Prophylaxis FDA asked all manufacturers to remove product from the market on April 1, 2020.
Morphine Sulfate/Naltrexone HCl (Embeda®) Opioid Analgesic – Extended Release Abuse Deterrent Pain Stop sale date November 15, 2019 with anticipated unavailability early 2020.
  • Stay Informed - Subscribe Today

  • This field is for validation purposes and should be left unchanged.